Sfondo Header
L'angolo del dottorino
Contents
Search the site... Advanced search
✖

Complications of congenital heart disease

Complications of congenital heart disease arise from interactions among the original anatomy, cardiovascular adaptation, treatment sequelae, and conditions that accumulate over a lifetime. An effective repair may eliminate a shunt or obstruction yet leave behind a regurgitant valve, an arrhythmogenic scar, or a ventricle subjected to an unusual load. Conversely, some simple anomalies have minimal effects for decades. Assessment must therefore distinguish the anatomical diagnosis from the current physiological state, which is more directly related to symptoms, risk, and the need for intervention.

The concept of a complication encompasses acute events and gradual changes: loss of exercise capacity, onset of congestion, rhythm disturbances, pulmonary vascular damage, infections, and effects on the liver, kidneys, or nervous system. These processes rarely occur in isolation. An arrhythmia may destabilize an already limited circulation, while a neglected valve lesion may progressively promote dilation and arrhythmias. Recognizing the links between different problems makes it possible to treat the cause of deterioration as well as its most obvious manifestation.

From anatomy to assessment of risk over time

Reconstructing the anatomical and surgical history is the first step. The name of the heart defect does not necessarily specify the circulation currently present: transposition corrected by an atrial switch has different consequences from transposition corrected by an arterial switch, and single-ventricle palliation is not equivalent to biventricular repair. Operative reports, catheterization records, and previous imaging clarify venous pathways, conduits, patches, and devices. This knowledge is essential when planning new vascular access, interpreting hypoxemia, or assessing an electrophysiological procedure.

Residual lesions are those persisting after treatment; other abnormalities arise later through prosthetic degeneration, bodily growth, vascular progression, or remodeling. The distinction changes the interpretation of follow-up: a small, unchanged regurgitant lesion and one that is worsening have different implications, even when today's report uses the same descriptive grade. Longitudinal comparison must take measurements, methodology, and hemodynamic conditions into account, because technical variation can mimic progression. In children, measurements must also be related to growth.

Assessing functional capacity requires specific questions about activities performed. Someone who has gradually reduced physical activity may report feeling well despite having lost a substantial proportion of their cardiovascular reserve. Cardiopulmonary exercise testing, walking assessment, and oxygen saturation during exertion, selected according to the clinical problem, help objectify this trajectory. No single marker replaces the overall clinical picture: biomarkers, ventricular function, rhythm, and performance may be discordant in congenital anatomy and must be interpreted together.

Surveillance combines echocardiography, electrocardiography, and selected investigations. Cardiac magnetic resonance imaging is particularly useful for volumes, flows, and the right ventricle; CT addresses questions concerning coronary arteries, calcifications, airways, and extracardiac relationships. Catheterization remains valuable when pressures and resistances need to be measured or a discrepancy that would change management needs to be clarified. Repeating tests should address a clinical question, while keeping acquisitions comparable and limiting unnecessary exposure.

Volume and pressure overload, ventricular dysfunction, and mechanical lesions

Volume overload arises, for example, from regurgitation or a persistent shunt; pressure overload arises from obstruction or a high-resistance vascular bed. Initially, the ventricle may compensate by changing its size and mass, but this adaptation is not unlimited. As filling pressures, fibrosis, or contractile inefficiency increase, symptoms may develop even before a marked reduction in ejection fraction. The type of ventricle supporting the systemic circulation and the presence of single-ventricle physiology alter the significance of conventional measurements.

Heart failure in congenital heart disease may result from reduced contractility, impaired filling, valvular incompetence, dyssynchrony, or failure of the circulation as a whole. Edema and fatigue therefore do not automatically establish a primary cardiomyopathy. Before intensifying medication, potentially correctable causes, such as conduit stenosis, significant regurgitation, or persistent arrhythmia, must be sought. Treatment of acquired left-sided heart failure provides useful tools, but the strength of the evidence varies across different congenital anatomies.

Valves and conduits may become stenotic or regurgitant after years of satisfactory function. The decision to reintervene considers ventricular consequences, functional capacity, and procedural risk rather than invariably waiting for advanced symptoms. When delayed correction leaves remodeling that is poorly reversible, technical success does not equate to full recovery. Serial data are therefore particularly valuable: they help identify when intervention may preserve function without undertaking it prematurely on the basis of a single uncertain measurement.

Other mechanical complications involve the aorta and coronary arteries, anastomotic sites, and reconstructed venous pathways. Venous obstruction may cause regional congestion or impair filling, while aortic dilation and coronary narrowing require assessments specific to the anatomy and previous surgery. Chest pain and syncope should not automatically be attributed to known heart disease, but neither should they be interpreted without considering reimplanted coronary arteries or congenital anomalies. The likelihood of concomitant atherosclerotic disease also increases with age.

Hypoxemia, pulmonary hypertension, and hematologic consequences

Cyanosis in congenital heart disease may arise from right-to-left flow, mixing, reduced pulmonary blood flow, or abnormal venous pathways. Skin color does not directly measure oxygen delivery, which is also affected by hemoglobin and cardiac output. A low but stable oxygen saturation and a sudden decline require different interpretations; in the latter situation, factors such as respiratory infection, thrombosis, dehydration, or worsening circulation must be investigated. Supplemental oxygen does not necessarily correct blood flow that bypasses the lungs through a shunt.

Secondary erythrocytosis is an adaptation to reduced oxygenation and must not be treated as primary polycythemia. Testing for iron deficiency is important even when hemoglobin appears elevated relative to usual reference values. Repeated phlebotomy without an appropriate indication can reduce oxygen-carrying capacity and promote iron deficiency. When headache or nonspecific symptoms occur, hydration, iron status, neurological causes, and other conditions should be considered before attributing them to hyperviscosity. Indicated iron supplementation requires clinical and laboratory monitoring.

Pulmonary hypertension has different mechanisms. Elevated pulmonary arterial pressure may reflect increased flow, precapillary vascular disease, elevated left-sided filling pressures, or combined components. Invasive measurements, when required, must distinguish these situations, because the implications for shunt closure and medication differ. Eisenmenger syndrome refers to progression of a systemic-to-pulmonary shunt to advanced vascular disease with a right-to-left component; it is not synonymous with every cyanotic congenital heart defect.

The combination of chronic hypoxemia, platelet abnormalities, and coagulation changes creates vulnerability to both thrombotic and bleeding events. Local thrombosis or paradoxical embolism may coexist with epistaxis or hemoptysis; anticoagulation must therefore be based on defined indications. The presence of a shunt also demands careful removal of air from venous lines. A neurological deficit, significant hemoptysis, or a sudden reduction in oxygen saturation requires urgent assessment rather than waiting for a scheduled appointment.

Arrhythmias, thromboembolism, and endocarditis

Arrhythmias in congenital heart disease can develop because of dilation, fibrosis, surgical scars, or abnormalities of the conduction system. Even a relatively slow atrial tachycardia can impair a filling-dependent circulation, while bradycardia can restrict output during activity. Palpitations require electrocardiographic documentation and correlation with symptoms; a normal ECG between episodes does not resolve the question. Syncope and sustained ventricular arrhythmias require risk assessment distinct from that used for isolated premature beats.

Rhythm management must integrate medication, ablation, devices, and hemodynamic correction. Access to a cardiac chamber may be altered by patches and baffles, and an arrhythmia circuit may traverse isthmuses created by previous operations. Pacemaker implantation likewise requires careful planning of lead location, access, thrombotic risk, and the effects of pacing on synchrony. In pediatric patients, growth and the anticipated duration of treatment further affect decisions; criteria derived from structurally normal hearts cannot always be transferred without adjustment.

Thromboembolism prevention depends on rhythm, anatomy, prostheses, function, and previous events. Common risk scores may not fully represent risk in complex congenital disease and unusual circulations. Antithrombotic selection also requires attention to bleeding, renal and hepatic function, and potential interactions. Perioperative interruption must be planned with reference to the original indication, rather than reducing the entire assessment to the presence or absence of atrial fibrillation.

Infective endocarditis can affect native valves, prostheses, and implanted material. Persistent fever, bacteremia, or hemodynamic deterioration warrants consideration of endocarditis even when initial echocardiography is inconclusive; devices and complex anatomy may necessitate additional imaging methods. Oral hygiene and treatment of infectious foci provide general prevention. Antibiotic prophylaxis does not apply indiscriminately to all congenital heart disease but to specific high-risk conditions and procedures defined by guidelines; it must be distinguished from therapeutic antibiotic use for suspected infection.

Organ damage, development, and effects on daily life

Chronic venous congestion and reduced cardiac output can affect the liver, kidneys, and lymphatic system. In the Fontan circulation, pulmonary blood flow without a dedicated pumping ventricle produces distinctive physiology: high venous pressures and reduced reserve may cause complications even with relatively preserved contractility. Fontan circulation failure must therefore be assessed as a problem affecting the circuit and the organs, rather than identified solely with a low ejection fraction.

Renal function influences tolerance of diuretics, drug selection, and the risk of contrast-enhanced procedures. In cyanotic patients or those with reduced muscle mass, laboratory results require clinical interpretation and comparison over time. Liver abnormalities may likewise reflect congestion or more advanced disease; minimally altered biochemical markers do not necessarily rule out structural damage. This information becomes particularly important when considering reintervention, advanced therapy, or transplantation.

Neurodevelopmental outcomes depend on genetic, prenatal, hemodynamic, and care-related factors, with needs potentially emerging at different stages. Successful cardiac repair does not exclude difficulties with attention, executive function, or schooling; surveillance should promote recognition and intervention without waiting for overt failure. In adults, anxiety, depression, and fear of physical activity may affect adherence and quality of life. Psychological and social support should accompany organ-directed treatment, particularly during transitions and repeated hospitalizations.

Reproductive risk encompasses maternal hemodynamics, medication, and the possibility of recurrence of the heart defect. Preconception assessment allows treatable problems to be addressed and contraception and pregnancy to be discussed on the basis of the specific physiology. Some conditions, such as advanced pulmonary arterial hypertension, carry very high risks. Genetic counseling is indicated when family history, an associated syndrome, or features of the malformation warrant it and must be distinguished from obstetric-cardiology assessment alone.

Prevention, warning signs, and continuity of care

Prevention consists of maintaining risk-appropriate surveillance and promptly treating modifiable causes. Blood pressure, metabolic risk factors, oral health, tailored physical activity, and treatment adherence remain important even when the malformation dominates clinical attention. Sedentary behavior does not automatically protect the heart, while exercise and sports require recommendations consistent with function, rhythm, aortic status, and oxygen saturation. A comprehensible care plan enables patients to participate in care without treating every change as an emergency.

Syncope, persistent tachycardia, new chest pain, rapidly worsening dyspnea, cyanosis differing from baseline, hemoptysis, and neurological symptoms require prompt assessment. In infants, reduced feeding, sweating, lethargy, and signs of poor perfusion are important. Symptoms must be interpreted against baseline values, but chronic illness must not lead clinicians to normalize acute deterioration. In emergencies, knowledge of anatomy and previous interventions guides stabilization, access, and specialist consultation.

Noncardiac procedures require planning proportionate to physiological complexity. Sedation, ventilation, and changes in circulating volume may alter filling and shunt direction, particularly in cyanotic patients or those with single-ventricle circulation. Discussion among the cardiologist, anesthetist, and proceduralist clarifies which medications to continue, how to manage antithrombotic treatment, and what postoperative care is needed. A previous assessment remains a useful reference but must be updated when symptoms, function, or the planned intervention have changed; stability at a remote visit does not necessarily describe current risk.

Transition to adult care requires an organized transfer of information and responsibilities, not merely a new appointment. A clinical summary listing diagnoses, operations, devices, medications, and active problems reduces errors in routine care and emergencies. The frequency of follow-up may change, but the absence of symptoms must not interrupt surveillance when risk persists. The goal is to detect deterioration while therapeutic options remain effective, preserving function, independence, and participation in daily life.

References
  1. Gurvitz M et al. 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2026;87(7):822-976.
  2. Baumgartner H et al. 2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal. 2021;42(6):563-645.
  3. Budts W et al. Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology. European Heart Journal. 2016;37(18):1419-1427.
  4. Hernández-Madrid A et al. Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital Heart Disease, endorsed by HRS, PACES, APHRS, and SOLAECE. Europace. 2018;20(11):1719-1753.
  5. Fratz S et al. Guidelines and protocols for cardiovascular magnetic resonance in children and adults with congenital heart disease: SCMR expert consensus group on congenital heart disease. Journal of Cardiovascular Magnetic Resonance. 2013;15(1):51.
  6. Han BK et al. Computed Tomography Imaging in Patients with Congenital Heart Disease Part I: Rationale and Utility. An Expert Consensus Document of the Society of Cardiovascular Computed Tomography (SCCT): Endorsed by the Society of Pediatric Radiology (SPR) and the North American Society of Cardiac Imaging (NASCI). Journal of Cardiovascular Computed Tomography. 2015;9(6):475-492.
  7. Khalil M et al. Acute therapy of newborns with critical congenital heart disease. Translational Pediatrics. 2019;8(2):114-126.
  8. Tay ELW et al. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. International Journal of Cardiology. 2011;151(3):307-312.
  9. Humbert M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618-3731.
  10. Shah MJ et al. 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients. Heart Rhythm. 2021;18(11):1888-1924.
  11. Delgado V et al. 2023 ESC Guidelines for the management of endocarditis. European Heart Journal. 2023;44(39):3948-4042.
  12. Rychik J et al. Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association. Circulation. 2019;140(6):e234-e284.
  13. Sood E et al. Neurodevelopmental Outcomes for Individuals With Congenital Heart Disease: Updates in Neuroprotection, Risk-Stratification, Evaluation, and Management: A Scientific Statement From the American Heart Association. Circulation. 2024;149(13):e997-e1022.
  14. De Backer J et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. European Heart Journal. 2025;46(43):4462-4568.
  15. Pierpont ME et al. Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association. Circulation. 2018;138(21):e653-e711.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.